株探米国株
英語
エドガーで原本を確認する
6-K 1 zk2228873.htm 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549


F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2022

TRINITY BIOTECH PLC
(Name of Registrant)

IDA Business Park
Bray, Co. Wicklow, Ireland
 (Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐      

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):          

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):          

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐    No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-               

This Form 6-K is being incorporated by reference into our Registration Statement on Form F-3 (File No. 333-264992)



 EXPLANATORY NOTE

On December 09, 2022, Trinity Biotech plc. issued a press release announcing the timing of the release of its third quarter 2022 financial results.  A copy of the press release is filed herewith as Exhibit 99.1.





EXHIBIT INDEX

Exhibit
 
Description
 
 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
TRINITY BIOTECH PLC
  
   
Trinity Biotech plc
  
   
(Registrant)
  
       
 
By:
/s/ John Gillard
  
   
John Gillard
  
   
Chief Financial Officer
  

Date:  December 09, 2022
EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1
Exhibit 99.1


Trinity Biotech plc to Announce Third Quarter
Fiscal Year 2022 Financial Results

Conference Call Scheduled for December 15, 2022
at 11:00 am EASTERN

DUBLIN – December 9, 2022 – Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2022 on Thursday, December 15, 2022. The Company has scheduled a conference call for that same day, December 15, 2022 at 11:00am ET (16:00pm GMT) to discuss the results of the quarter.

Interested parties can access the call by dialing:
 
US Toll Free:
1-844-861-5499
 
International Toll:
1-412-317-6581
 
Ireland Toll:
014311269
 
Ireland Toll Free:
1800932830
Please ask to be joined into the Trinity Biotech call.

A simultaneous webcast of the call can be accessed at:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=XpdogyA1

A replay of the call can be accessed until December 22, 2022 by dialing:
 
US Toll Free:
1-877-344-7529
 
International Toll:
1-412-317-0088

Canada Free Toll:
1-855-669-9658
 
Replay Code:
4932074

To access the replay using an international dial-in number, please see the link below:
https://services.choruscall.com/ccforms/replay.html

A webcast of the call will be available for 30 days  at:  
https://event.choruscall.com/mediaframe/webcast.html?webcastid=XpdogyA1

Replays will be available 1 hour after the end of the conference.



Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve known and unknown risks and uncertainties.  Many factors could cause the actual results, performance or achievements of Trinity Biotech to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the results of research and development efforts, risks associated with the outbreak and global spread of the coronavirus (COVID-19), the effect of regulation by the U.S. Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties.  For additional information regarding these and other risks and uncertainties associated with Trinity Biotech’s business, reference is made to our reports filed from time to time with the U.S. Securities and Exchange Commission.  We undertake no obligation to update or revise any forward-looking statements for any reason.
 
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
 
Contact
John Gillard
Trinity Biotech plc
(353)-1-2769800

Joe Diaz
Lytham Partners, LLC
Investor Relations
(1)-602-889-9700
E-mail:  investorrelations@trinitybiotech